Lipid lowering activity of lercanidipine in hyperlipidemic rats

Iranian Journal of Pharmacology and Therapeutics

Volumn 9, Issue 2, 2010, Pages 73-75

  Prasanna Kumar, K ^a   Rama Narsimha Reddy, A ^b   Narsimha Reddy, Y ^b   Anbu, J ^a  

^a VELS INSTITUTE OF SCIENCE   (India)

^b KAKATIYA UNIVERSITY   (India)

Author keywords

Atorvastatin; Hyperlipidemic rats; Lercanidipine; Lipid lowering activity

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LERCANIDIPINE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; HYPERLIPIDEMIA; LIPID LOWERING ACTIVITY; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; RAT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 78649808628     PISSN: 17352657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Raasch RH, Hyperlipidemias, in Applied Therapeutics. The Clinical Use of Drugs edited by Young LY andKoda-Kimble MA (Edwards Brothers, Ann Arbor, MI) 1988;9: 1743.
2. Augusti KT, Narayana Aswathy, Lekhespillai, Razia S, Beneficial effects of garlic (allium sativum LMN) on rats fed with diets containing cholesterol and either of the oil seeds, coconuts (or) groundnuts, Indian J Exp Biol.2001;39: 660.
3. Markku J. Savolainen, Maire Rantala, Kari Kervinen, Leea Järvi, Kaisu Suvanto, Tapio Rantala & Y. Antero Kesäniemi, Magnitude of dietary effects on plasma cholesterol concentration: role of sex and apolipoprotein E phenotype, Atherosclerosis, 1991;86: 145.
4. Wanner C, Quaschning T., Dyslipidemia and renal disease: pathogenesis and clinical consequences, Curr Opin Nephrol Hypertens, 2001; 10:195.
5. Cherylyn Beckey, PharmD CDE, Lercanidipine in the Treatment of Hypertension, The Annals of Pharmacotherapy, 2007; 41:465.
6. Gulati R, Agarwal DK, Hossain MM, Ali R, Srivastava U, Study of serum lipid profile changes in Met-Enkephalm treated rats, Indian J. Physiol Pharmacol, 2003; 47:357.
7. Massicotte Julie, Viens antoime, Yao-Ming-Hui, et al., Effects of Lercanidipine on coronary reactivity and myocardial remodeling in transition to heart failure in cardiomyopathic hamsters, Acta Pharmacol, 2003;24:199.
8. V.T. Friedewald, R.I. Levy and D.S. Fredrickson, Estimation of low-density lipoprotein cholesterol in plasma, without use of the preparative centrifuge, Clin Chem.,1972;18:499.
9. Ralph H, Stern Ph.D M.D, Bing-Bing YoungPh.D, Neil.J, Hormslow M.D, Mark MacMahon, M.D. Robert B. Abel Ph.D, and Stephen C, Olson Ph.D, Pharmacodynamics and pharmacokinetics pharmacodynamic relationships of atorvastatin, an HMG-COA reductase inhibitor, J clin pharmacal 2000;40:616.
10. Epstein M, Lercanidipine: a novel dihydropyridine calcium-channel blocker, Heart Dis., 2001; 3:398.
11. Stefano Bellosta and Franco Bernini, Lipophilic calcium antagonists in antiatherosclerotic therapy, J Curt Atherosclerosis Reports, 2000; 2:76.
12. J. Wouter Jukema, Ad J. van Boven, Aeilko H. Zwinderman, Arnoud Van der Laarse and Albert V.G. Bruschke, Proposed Synergistic Effect of Calcium Channel Blockers with Lipid-Lowering Therapy in Retarding Progression of Coronary Atherosclerosis, Journal of Cardiovascular Drugs and Therapy, 1998; 12:111.
13. Maurizio R. Soma, Malvina Natali, Elena Donetti, Roberta Baetta, Pierluigi Farina, Amedeo Leonardi, Carmen Comparato, Laura Barberi & 1,2,5 Alberico L. Catapano, Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits, British J Pharmacol 1998;125:1471.
14. Catapano, AL, Calcium antagonists and atherosclerosis. Experimental evidence, Eur Heart J 1997; 18:80.